WO2013182503A1 - Rapamycin 40-o-cyclic hydrocarbon esters, compositions and methods - Google Patents
Rapamycin 40-o-cyclic hydrocarbon esters, compositions and methods Download PDFInfo
- Publication number
- WO2013182503A1 WO2013182503A1 PCT/EP2013/061343 EP2013061343W WO2013182503A1 WO 2013182503 A1 WO2013182503 A1 WO 2013182503A1 EP 2013061343 W EP2013061343 W EP 2013061343W WO 2013182503 A1 WO2013182503 A1 WO 2013182503A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- poly
- rapamycin
- stent
- lactide
- cyclic hydrocarbon
- Prior art date
Links
- 0 *C(C1CCCC1)=O Chemical compound *C(C1CCCC1)=O 0.000 description 4
- LJRNTMAPSJFZPV-UHFFFAOYSA-N CC(C)C(C(CC(C1O)O)=CC1O)=O Chemical compound CC(C)C(C(CC(C1O)O)=CC1O)=O LJRNTMAPSJFZPV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
- C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
- A61L2300/608—Coatings having two or more layers
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK13727586.3T DK2859001T3 (en) | 2012-06-08 | 2013-06-03 | RAPAMYCIN 40-O-CYCLIC HYDROCARBESTERS, COMPOSITIONS AND PROCEDURES |
CA2869102A CA2869102C (en) | 2012-06-08 | 2013-06-03 | Rapamycin 40-o-cyclic hydrocarbon esters, compositions and methods |
EP13727586.3A EP2859001B1 (en) | 2012-06-08 | 2013-06-03 | Rapamycin 40-o-cyclic hydrocarbon esters, compositions and methods |
SG11201405777YA SG11201405777YA (en) | 2012-06-08 | 2013-06-03 | Rapamycin 40-o-cyclic hydrocarbon esters, compositions and methods |
CN201380010936.6A CN104203959B (en) | 2012-06-08 | 2013-06-03 | The O cyclic hydrocarbons ester of rapamycin 40, composition and method |
ES13727586.3T ES2574522T3 (en) | 2012-06-08 | 2013-06-03 | 40-O-cyclic rapamycin hydrocarbon esters, compositions and procedures |
AU2013270798A AU2013270798B2 (en) | 2012-06-08 | 2013-06-03 | Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods |
PL13727586T PL2859001T3 (en) | 2012-06-08 | 2013-06-03 | Rapamycin 40-o-cyclic hydrocarbon esters, compositions and methods |
US14/406,198 US9408884B2 (en) | 2012-06-08 | 2013-06-03 | Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods |
JP2015515488A JP6101346B2 (en) | 2012-06-08 | 2013-06-03 | Rapamycin-40-O-cyclic hydrocarbon ester, composition and method |
US15/212,987 US9867911B2 (en) | 2012-06-08 | 2016-07-18 | Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods |
US15/829,012 US20180078683A1 (en) | 2012-06-08 | 2017-12-01 | Rapamycin 40-O-Cyclic Hydrocarbon Esters, Compositions and Methods |
US16/359,187 US10751450B2 (en) | 2012-06-08 | 2019-03-20 | Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods |
US16/933,821 US11383009B2 (en) | 2012-06-08 | 2020-07-20 | Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261657049P | 2012-06-08 | 2012-06-08 | |
US61/657,049 | 2012-06-08 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/406,198 A-371-Of-International US9408884B2 (en) | 2012-06-08 | 2013-06-03 | Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods |
US15/212,987 Continuation US9867911B2 (en) | 2012-06-08 | 2016-07-18 | Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013182503A1 true WO2013182503A1 (en) | 2013-12-12 |
Family
ID=48577737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2013/061343 WO2013182503A1 (en) | 2012-06-08 | 2013-06-03 | Rapamycin 40-o-cyclic hydrocarbon esters, compositions and methods |
Country Status (11)
Country | Link |
---|---|
US (3) | US9408884B2 (en) |
EP (1) | EP2859001B1 (en) |
JP (1) | JP6101346B2 (en) |
CN (1) | CN104203959B (en) |
AU (1) | AU2013270798B2 (en) |
CA (1) | CA2869102C (en) |
DK (1) | DK2859001T3 (en) |
ES (1) | ES2574522T3 (en) |
PL (1) | PL2859001T3 (en) |
SG (1) | SG11201405777YA (en) |
WO (1) | WO2013182503A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018050916A1 (en) * | 2016-09-19 | 2018-03-22 | Biotronik Ag | Polymer-free drug eluting vascular stents |
WO2018114992A1 (en) * | 2016-12-22 | 2018-06-28 | Biotronik Ag | Drug releasing coatings for medical devices and methods of making same |
WO2019162048A1 (en) * | 2018-02-23 | 2019-08-29 | Biotronik Ag | Parenteral formulation materials and methods for 40-o-cyclic hydrocarbon esters and related structures |
CN111344025A (en) * | 2017-12-06 | 2020-06-26 | 百多力股份公司 | Intracranial drug delivery materials and methods |
WO2020157044A1 (en) * | 2019-01-30 | 2020-08-06 | Biotronik Ag | Covered stent for local drug delivery |
WO2022023414A3 (en) * | 2020-07-29 | 2022-07-14 | Biotronik Ag | Pharmaceutical microsphere compositions and methods |
WO2024068153A1 (en) * | 2022-09-30 | 2024-04-04 | Biotronik Ag | Macrocyclic triene immunosuppressive compounds for perivascular medical treatment of vascular access fistulas, grafts and other vascular conditions |
WO2024068159A1 (en) * | 2022-09-30 | 2024-04-04 | Biotronik Ag | Synthesis and characterization of cyclic hydrocarbon esters of everolimus |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9408884B2 (en) * | 2012-06-08 | 2016-08-09 | Biotronik Ag | Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods |
US10751450B2 (en) * | 2012-06-08 | 2020-08-25 | Biotronik Ag | Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods |
US11395853B2 (en) * | 2016-06-23 | 2022-07-26 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions |
CN107759616B (en) * | 2016-08-23 | 2020-11-17 | 上海微创医疗器械(集团)有限公司 | Compound and preparation method and application thereof |
Citations (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3929992A (en) | 1972-09-29 | 1975-12-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
US3993749A (en) | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
US4316885A (en) | 1980-08-25 | 1982-02-23 | Ayerst, Mckenna And Harrison, Inc. | Acyl derivatives of rapamycin |
US4650803A (en) | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
US5102876A (en) | 1991-05-07 | 1992-04-07 | American Home Products Corporation | Reduction products of rapamycin |
US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
US5120727A (en) | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Rapamycin dimers |
US5120725A (en) | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Bicyclic rapamycins |
US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
US5135740A (en) | 1988-04-22 | 1992-08-04 | Advanced Polymer Systems, Inc. | Porous particles in preparations involving immiscible phases |
US5138051A (en) | 1991-08-07 | 1992-08-11 | American Home Products Corporation | Rapamycin analogs as immunosuppressants and antifungals |
US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
US5310903A (en) | 1993-03-05 | 1994-05-10 | Merck & Co., Inc. | Imidazolidyl rapamycin derivatives |
US5665772A (en) | 1992-10-09 | 1997-09-09 | Sandoz Ltd. | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
WO2004101583A1 (en) * | 2003-05-16 | 2004-11-25 | Isotechnika Inc. | Rapamycin carbohydrate derivatives |
WO2005042567A1 (en) * | 2003-11-03 | 2005-05-12 | Altachem Pharma Ltd. | Rapamycin peptides conjugates: synthesis and uses thereof |
US7214759B2 (en) | 2004-11-24 | 2007-05-08 | Advanced Cardiovascular Systems, Inc. | Biologically absorbable coatings for implantable devices based on polyesters and methods for fabricating the same |
WO2008033956A2 (en) * | 2006-09-13 | 2008-03-20 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
US7572245B2 (en) | 2003-09-15 | 2009-08-11 | Atrium Medical Corporation | Application of a therapeutic substance to a tissue location using an expandable medical device |
US7750041B2 (en) | 2001-03-26 | 2010-07-06 | Bayer Schering Pharma Aktiengesellschaft | Preparation for the prophylaxis of restenosis |
WO2012017449A1 (en) * | 2010-08-04 | 2012-02-09 | Meril Life Sciences Pvt. Ltd | Process for preparation of novel 42-0-(heteroalkoxyalkyl) rapamycin compounds with anti-proliferative properties" |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0729471A1 (en) * | 1993-11-19 | 1996-09-04 | Abbott Laboratories | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
US5385910A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Gem-distributed esters of rapamycin |
US6939376B2 (en) * | 2001-11-05 | 2005-09-06 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
CN101467921B (en) * | 2001-11-05 | 2012-08-15 | 生物传感器国际集团有限公司 | Method for producing bracket for eluting medicament |
EP1737869A1 (en) * | 2004-04-14 | 2007-01-03 | Wyeth a Corporation of the State of Delaware | Regiospecific synthesis of rapamycin 42-ester derivatives |
US8021678B2 (en) * | 2006-02-10 | 2011-09-20 | Advanced Cardiovascular Systems, Inc. | Implantable medical device with polymer coating in a surface area to volume ratio providing surface erosion characteristics |
US7678901B2 (en) * | 2006-02-28 | 2010-03-16 | Wyeth | Rapamycin analogs containing an antioxidant moiety |
MX2008011458A (en) * | 2006-03-07 | 2008-09-24 | Wyeth Corp | Process for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants. |
US20110098241A1 (en) * | 2008-04-14 | 2011-04-28 | Poniard Pharmaceuticals, Inc. | Rapamycin analogs as anti-cancer agents |
CN102018996B (en) * | 2010-12-14 | 2013-03-06 | 中国医学科学院生物医学工程研究所 | Manufacturing method of drug vessel support with antibody immobilized on surface of support |
DE102011010539A1 (en) | 2011-02-07 | 2012-08-09 | Airbus Operations Gmbh | An upgrading device and method for producing a fuselage for an aircraft consisting of a fiber composite material |
US9408884B2 (en) * | 2012-06-08 | 2016-08-09 | Biotronik Ag | Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods |
-
2013
- 2013-06-03 US US14/406,198 patent/US9408884B2/en active Active
- 2013-06-03 DK DK13727586.3T patent/DK2859001T3/en active
- 2013-06-03 WO PCT/EP2013/061343 patent/WO2013182503A1/en active Application Filing
- 2013-06-03 EP EP13727586.3A patent/EP2859001B1/en active Active
- 2013-06-03 SG SG11201405777YA patent/SG11201405777YA/en unknown
- 2013-06-03 JP JP2015515488A patent/JP6101346B2/en active Active
- 2013-06-03 ES ES13727586.3T patent/ES2574522T3/en active Active
- 2013-06-03 AU AU2013270798A patent/AU2013270798B2/en active Active
- 2013-06-03 CN CN201380010936.6A patent/CN104203959B/en active Active
- 2013-06-03 CA CA2869102A patent/CA2869102C/en active Active
- 2013-06-03 PL PL13727586T patent/PL2859001T3/en unknown
-
2016
- 2016-07-18 US US15/212,987 patent/US9867911B2/en active Active
-
2017
- 2017-12-01 US US15/829,012 patent/US20180078683A1/en not_active Abandoned
Patent Citations (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3929992A (en) | 1972-09-29 | 1975-12-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
US3993749A (en) | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
US4316885A (en) | 1980-08-25 | 1982-02-23 | Ayerst, Mckenna And Harrison, Inc. | Acyl derivatives of rapamycin |
US4650803A (en) | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
US5135740A (en) | 1988-04-22 | 1992-08-04 | Advanced Polymer Systems, Inc. | Porous particles in preparations involving immiscible phases |
US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
US5120842B1 (en) | 1991-04-01 | 1993-07-06 | A Failli Amedeo | |
US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
US5102876A (en) | 1991-05-07 | 1992-04-07 | American Home Products Corporation | Reduction products of rapamycin |
US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
US5120725A (en) | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Bicyclic rapamycins |
US5120727A (en) | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Rapamycin dimers |
US5138051A (en) | 1991-08-07 | 1992-08-11 | American Home Products Corporation | Rapamycin analogs as immunosuppressants and antifungals |
US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
US5665772A (en) | 1992-10-09 | 1997-09-09 | Sandoz Ltd. | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
US6440990B1 (en) | 1992-10-09 | 2002-08-27 | Novartis Ag | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
US5310903A (en) | 1993-03-05 | 1994-05-10 | Merck & Co., Inc. | Imidazolidyl rapamycin derivatives |
US7750041B2 (en) | 2001-03-26 | 2010-07-06 | Bayer Schering Pharma Aktiengesellschaft | Preparation for the prophylaxis of restenosis |
WO2004101583A1 (en) * | 2003-05-16 | 2004-11-25 | Isotechnika Inc. | Rapamycin carbohydrate derivatives |
US7572245B2 (en) | 2003-09-15 | 2009-08-11 | Atrium Medical Corporation | Application of a therapeutic substance to a tissue location using an expandable medical device |
WO2005042567A1 (en) * | 2003-11-03 | 2005-05-12 | Altachem Pharma Ltd. | Rapamycin peptides conjugates: synthesis and uses thereof |
US7214759B2 (en) | 2004-11-24 | 2007-05-08 | Advanced Cardiovascular Systems, Inc. | Biologically absorbable coatings for implantable devices based on polyesters and methods for fabricating the same |
WO2008033956A2 (en) * | 2006-09-13 | 2008-03-20 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
WO2012017449A1 (en) * | 2010-08-04 | 2012-02-09 | Meril Life Sciences Pvt. Ltd | Process for preparation of novel 42-0-(heteroalkoxyalkyl) rapamycin compounds with anti-proliferative properties" |
Non-Patent Citations (5)
Title |
---|
ADAMCZYK ET AL.: "Lipase Mediated Hydrolysis of Rapamycin 42-Hemisuccinate Benzyl and Methyl Esters", TETRAHEDRON LETTERS, vol. 35, no. 7, 1994, pages 1019 - 1022, XP002218069, DOI: doi:10.1016/S0040-4039(00)79954-0 |
HAMON, M. ET AL., DRUG THERAPY, vol. 4, 1998, pages 261 - 301 |
HOFFMAN, R. ET AL., CIRCULATION, vol. 94, 1996, pages 1247 - 1254 |
OESTERLE, S. ET AL., AM. HEART J., vol. 136, 1998, pages 578 - 599 |
VEZINA ET AL., J. ANTIBIOT., vol. 28, 1975, pages 721 |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018050916A1 (en) * | 2016-09-19 | 2018-03-22 | Biotronik Ag | Polymer-free drug eluting vascular stents |
CN109715224A (en) * | 2016-09-19 | 2019-05-03 | 百多力股份公司 | The drug eluting vascular bracket of non-polymer |
CN109715224B (en) * | 2016-09-19 | 2022-02-22 | 百多力股份公司 | Polymer-free drug-eluting vascular stent |
WO2018114992A1 (en) * | 2016-12-22 | 2018-06-28 | Biotronik Ag | Drug releasing coatings for medical devices and methods of making same |
WO2018114989A1 (en) * | 2016-12-22 | 2018-06-28 | Biotronik Ag | Intratumoral drug delivery materials and methods for treating breast cancer |
US11826492B2 (en) | 2016-12-22 | 2023-11-28 | Biotronik Ag | Intratumoral drug delivery materials and methods for treating breast cancer |
CN111344025A (en) * | 2017-12-06 | 2020-06-26 | 百多力股份公司 | Intracranial drug delivery materials and methods |
WO2019162048A1 (en) * | 2018-02-23 | 2019-08-29 | Biotronik Ag | Parenteral formulation materials and methods for 40-o-cyclic hydrocarbon esters and related structures |
WO2020157044A1 (en) * | 2019-01-30 | 2020-08-06 | Biotronik Ag | Covered stent for local drug delivery |
WO2022023414A3 (en) * | 2020-07-29 | 2022-07-14 | Biotronik Ag | Pharmaceutical microsphere compositions and methods |
WO2024068153A1 (en) * | 2022-09-30 | 2024-04-04 | Biotronik Ag | Macrocyclic triene immunosuppressive compounds for perivascular medical treatment of vascular access fistulas, grafts and other vascular conditions |
WO2024068159A1 (en) * | 2022-09-30 | 2024-04-04 | Biotronik Ag | Synthesis and characterization of cyclic hydrocarbon esters of everolimus |
Also Published As
Publication number | Publication date |
---|---|
CA2869102C (en) | 2019-02-26 |
US9408884B2 (en) | 2016-08-09 |
US9867911B2 (en) | 2018-01-16 |
US20150297662A1 (en) | 2015-10-22 |
JP6101346B2 (en) | 2017-03-22 |
EP2859001A1 (en) | 2015-04-15 |
PL2859001T3 (en) | 2016-08-31 |
ES2574522T3 (en) | 2016-06-20 |
US20180078683A1 (en) | 2018-03-22 |
CA2869102A1 (en) | 2013-12-12 |
AU2013270798B2 (en) | 2017-09-07 |
JP2015518869A (en) | 2015-07-06 |
DK2859001T3 (en) | 2016-05-30 |
CN104203959B (en) | 2017-09-15 |
CN104203959A (en) | 2014-12-10 |
AU2013270798A1 (en) | 2015-01-29 |
EP2859001B1 (en) | 2016-04-13 |
US20170021065A1 (en) | 2017-01-26 |
SG11201405777YA (en) | 2014-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9867911B2 (en) | Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods | |
EP2258415B1 (en) | Medical devices containing rapamycin analogs | |
TWI435724B (en) | Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices | |
US20160220738A1 (en) | Progesterone-containing compositions and devices | |
US20050131008A1 (en) | 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same | |
EP2068932B1 (en) | Compositions and drug-delivery systems comprising rapamycin analogs and paclitaxel | |
EP1795185A2 (en) | Nano- and/or micro-particulate formulations for local injection-based treatment of vascular diseases | |
JP2011245297A (en) | Drug coated expandable device | |
JP6387359B2 (en) | Method for producing implantable medical device containing rapamycin derivative | |
EP2352459A1 (en) | Macrocyclic lactone compounds and methods for their use | |
EP2624834A1 (en) | Macrocyclic lactone compounds and methods for their use | |
US11383009B2 (en) | Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods | |
CN107865868B (en) | New application of amlexanox | |
JP2016523588A (en) | Hollow stent filled with therapeutic compound formulation | |
CN110772670A (en) | Limus coating and method of use thereof | |
EP3213721B1 (en) | Drug-eluting stent | |
KR20160122949A (en) | Drug releasing stent and manufacturing method of the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13727586 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2869102 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2015515488 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013727586 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: IDP00201407622 Country of ref document: ID |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14406198 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2013270798 Country of ref document: AU Date of ref document: 20130603 Kind code of ref document: A |